Back to search results
NCT03825120

The Longitudinal Evaluation of Ovarian Aging and Cardiovascular Risk

Enrolling by Invitation
Not specifiedAges 35–55Observational
University of California, San Francisco
~865 participants
Updated 2024-09-19 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in the EndoScore or reactive hyperemia ratio, an index of peripheral endothelial function, as assessed by the FDA-approved EndoPAT 2000
Measured over 2 times, once at each of 2 study visits ~1 year apart

Conditions

Infertility
Cardiovascular Risk Factor

Explore related trials

Cardiovascular DisorderInfertility

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Marcelle I Cedars, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Enrollment into the original OVA cohort (NCT00501800)

Exclusion

Not a member of the original OVA cohort

What this trial measures

  • Change in the EndoScore or reactive hyperemia ratio, an index of peripheral endothelial function, as assessed by the FDA-approved EndoPAT 20002 times, once at each of 2 study visits ~1 year apart

    Endothelium-mediated changes in vascular tone will be represented by the EndoScore or ratio of Reactive Hyperemia pre-occlusion to post-occlusion of the brachial artery (via blood pressure cuff). A score \> 1.67 is considered "normal" and a score \<= 1.67 is "abnormal". The EndoPAT 2000 machine will be used for this measure, which is the only non-invasive method of measuring endothelial function or the state of arterial health. Well-functioning arteries protect blood vessels from hardening (or atherosclerosis) and plaque build up. The EndoScore score will be the primary measure for cardiovascular (CV) disease risk, as actual CV event rates will be too low for many years